Eradication of Minimal Residual Disease (MRD) in Patients With Chronic Lymphocytic Leukaemia (CLL) With Alemtuzumab: A Phase II Study

Trial Profile

Eradication of Minimal Residual Disease (MRD) in Patients With Chronic Lymphocytic Leukaemia (CLL) With Alemtuzumab: A Phase II Study

Completed
Phase of Trial: Phase II

Latest Information Update: 29 Jun 2017

At a glance

  • Drugs Alemtuzumab (Primary)
  • Indications Chronic lymphocytic leukaemia
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 30 Aug 2014 Accrual to date is 112% according to United Kingdom Clinical Research Network record.
    • 10 Feb 2012 Actual end date (29 Feb 2008) added as reported by ISRCTN: Current Controlled Trials.
    • 10 Feb 2012 Status changed from active, no longer recruiting to completed as reported by as reported by ISRCTN: Current Controlled Trials.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top